Australian biotech company Ena Respiratory said that its nasal spray significantly mitigated Covid-19 virus levels in the nose and throat in a study on animals.

The treatment could potentially enhance the human immune system against common colds and flu.

INNA-051 is a synthetic small molecule self-administered via a nasal spray once or twice a week, used alone or along with vaccine programmes for Covid-19.

Researchers performed the study, published on biomedical prepublication research site bioRxiv, on ferrets. Led by Public Health England (PHE) scientists, the study showed that INNA-051 decreased viral replication by up to 96%.

On obtaining positive toxicity study results and regulatory approval, Ena Respiratory expects to progress the nasal spray into human trials within four months.

Ena Respiratory managing director Christophe Demaison said: “By boosting the natural immune response of the ferrets with our treatment, we’ve seen a rapid eradication of the virus.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“If humans respond in a similar way, the benefits of treatment are two-fold. Individuals exposed to the virus would most likely rapidly eliminate it, with the treatment ensuring that the disease does not progress beyond mild symptoms.”

The company secured approximately $8.24m (A$11.7m) in a funding round led by the Brandon Capital-managed Medical Research Commercialisation Fund (MRCF).

The Australian Government, AustralianSuper, HESTA, Hostplus, StatewideSuper, biotech firm CSL and Uniseed also contributed to the funding.

Uniseed CEO Dr Peter Devine noted: “These are very exciting results and demonstrate the potential clinical utility of the Ena drug in the treatment of Covid-19 which will likely require multiple treatment approaches.

“It also underlines the value of facilitating early-stage commercialisation of research, which can go on to create a global impact.”

The company plans to raise additional funds to speed-up the nasal spray’s clinical development and distribution worldwide.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now